Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine −

MustGrow Closes $3.7 Million Non-Brokered LIFE Offering

MustGrow Biologics Raises $3.7M to Fund TerraSante Biofertility Ramp Amid Persistent Cash Burn

By The Northwire Desk — AI Analysis Jun 19, 2026 · 17:01 MGRO · 0.44 MustGrow Biologics Corp.
Executive Summary
  • MustGrow Biologics Corp. closed a non-brokered private placement (LIFE Offering) on June 19, 2026.
  • Gross proceeds of approximately $3.74 million were raised by issuing 7,481,541 units at $0.50 per unit.
  • Each unit comprises one common share and one common share purchase warrant exercisable for 60 months at $0.70 per share.
  • Net proceeds are allocated to inventory production for the flagship TerraSante™ biofertility product, working capital, and general corporate purposes.
  • Finder compensation was set at 6.0% in cash fees plus 6.0% in non-transferable warrants.
  • The offering was conducted under the Listed Issuer Financing exemption (NI 45-106 Part 5A) and is subject to TSXV approval.
  • Capital structure context indicates ~70.4 million common shares outstanding prior to the offering, expanding to ~91.9 million on a fully diluted basis.
Material Impact
  • The financing directly addresses the company's severe liquidity constraints. Q1 2026 financials revealed only $0.42 million in cash and equivalents, with operating cash burn exceeding $2.28 million in the quarter.
  • The $3.74 million injection provides approximately 18 months of runway, assuming continued operational scaling and no major cost overruns.
  • The offering price of $0.50 is at a slight premium to the recent trading range ($0.44-$0.49), but the issuance of new shares and warrants introduces significant dilution. Fully diluted shares will increase by roughly 26%.
  • The use of proceeds aligns with management's stated pivot to commercialize TerraSante™ in the U.S., but does not alter the fundamental cash-burn profile of the business.
  • The market impact is expected to be neutral to slightly negative in the short term due to dilution, but the capital injection mitigates immediate bankruptcy risk.
MGRO · Price
Company Overview
  • MustGrow Biologics Corp. is an agricultural biologics company focused on developing and commercializing plant-based products.
  • Flagship product: TerraSante™, a mustard-derived organic biofertility product designed to improve soil microbiome health, nutrient/water use efficiency, and crop yields.
  • Pipeline product: TerraMG™, a biocontrol product targeting clubroot disease in canola, currently undergoing field trials and regulatory review in Canada.
  • The company previously operated a Canadian distribution arm, NexusBioAg, which has been wound down to focus resources on U.S. TerraSante™ sales.
  • The business model relies on third-party contract manufacturing and direct sales to U.S. farmers and retailers, with international expansion plans via partnerships like Bayer AG for EMEA.
Read the original news release →

More from MustGrow Biologics Corp.

Jun 17, 2026 · 19:22

MustGrow Biologics raises $3.7M to fund TerraSante ramp-up amid persistent cash burn.

Financings May 28, 2026 · 17:01

MustGrow Biologics Secures Liquidity Amidst Early Revenue Growth and Manufacturing Transition

Earnings May 25, 2026 · 18:01

MustGrow Biologics Secures Capital for U.S. Expansion Amidst Revenue Growth

Financings May 25, 2026 · 07:00

Regulatory Expansion Validates Growth Strategy But Cash Burn Remains Critical Risk

Regulatory May 14, 2026 · 17:15

MustGrow Biologics Corp.

Other Apr 29, 2026 · 17:01

MustGrow Biologics Revenue Surges 19x Amidst Strategic Pivot and Cash Burn Concerns

Earnings